IO Biotech appoints Helen Collins to board of directors

IO Biotech has announced the appointment of Helen Collins MD to its board of directors. Dr Collins has vast experience in oncology/haematology drug development and will now serve on the R&D Committee of the board.
Dr Collins has over 25 years of medical experience and is currently the chief medical officer of Enliven Therapeutics. Prior to this she worked as chief medical officer and executive vice president at Five Prime Therapeutics until its acquisition by Amgen in 2021. She has also worked in various roles at Gilead Sciences and Amgen, as well as being on the board at Kura Oncology.
Mai-Britt Zocca PhD, president and CEO of IO Biotech, stated: “We are pleased to welcome Helen, an accomplished healthcare executive with extensive drug development and corporate strategy experience, to our board of directors. I look forward to Helen’s contributions to the board as we work to potentially bring our lead cancer vaccine candidate, IO102-IO103, to market for patients with advanced melanoma as early as 2025.”
Commenting on her new role, Helen Collins stated: “I am inspired by IO Biotech’s unique approach that has the potential to transform the way many cancers are treated today. The phase 1/2 data of lO102-IO103 in combination with a PD-1 inhibitor to treat first-line advanced melanoma patients showed a remarkable overall response rate of 80% and the data generated from the company’s phase 2 study in patients with non-small cell lung cancer and squamous cell cancer of the head and neck is promising. I look forward to working with the company as they complete their pivotal phase 3 trial and work to fulfill their mission of changing the treatment paradigm for patients with cancer.”